Check 35,000+ stocks against 26 valuation models and 37 quality factors

Medacta Group (0A05) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of Medacta Group CHF 86.83, price CHF 113, upside -23.2%, quality 59 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? No
Good quality? Yes
Add to watchlist

Healthcare · GB · Home Switzerland · ISIN CH0468525222

MG Some data Sep 24, 2026

Medacta Group

0A05 · LSE

Overvalued / MonitorQuality is not strong enough to offset the price risk.

!Fair value CHF 86.83 · Overvalued (−23.2%)

!Quality 59/100

!Mixed Growth (revenue 5y +17.9 %/yr)

✓Solidly profitable · 14.0% net margin (TTM)

✓Low debt · generates free cash flow

✓1.0% dividend yield · Low payout

✓Wide moat 66/100

!Evidence only medium, so the estimate is less certain

!The models disagree: range CHF 43.40 to CHF 147.75

26 models, one by oneBear CHF 43.40 to bull CHF 147.75 Growth analysisrevenue history, year by year Quality 59/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch Medacta Group for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range CHF 77.33 – CHF 174.45 · fair‑value band CHF 43.40 – CHF 147.75 · the CHF 113.00 price screens above the CHF 86.83 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Medacta Group SA develops, manufactures, and distributes orthopedic and neurosurgical medical devices Latin America, North America, the Asia-Pacific, and Middle East and Africa. It offers personalized 3D planning tools for use in hip, knee, shoulder, joint replacement, sports medicine, and spine surgery.

Stock analysis

Medacta Group (0A05) currently trades at CHF 113.00, while our model-based Fair Value estimate is CHF 86.83, 23.2% below the price, so the stock looks overvalued today.

Valuation

Bull case: the Growth Earnings group reads highest at a median of CHF 87.38 per share, and 2 of the 26 models we run sit above the CHF 113.00 price.

Bear case: the Asset-Based group reads lowest at CHF 11.75, and 24 of the 26 models stay below the price. Evidence for this calculation is medium.

Scenario range: CHF 43.40 (bear) to CHF 147.75 (bull), the price of CHF 113.00 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 59/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Medacta Group reported revenue of CHF 688M in FY2025 versus CHF 363M in FY2021, a compound +17.3%/yr. Reported net income was CHF 96.1M in FY2025, compounding +16.9%/yr from FY2021.

Key figures

Market cap CHF 2.9B · P/E ratio 0.5 · P/S ratio 0.07 · EPS (TTM) CHF 2.62 · Dividend yield 1.0% · Net margin 14.0% · Return on equity 22.8% · Return on assets (EBIT) 11.0%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).

What moves the price

The share trades about 35% below its 52-week high and 4% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −23%, 0A05 screens richer than that median.

Fair Value models

Bear CHF 43.40 Fair Value CHF 86.83 Bull CHF 147.75

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (CHF 1.09 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

FCF DCF CHF 18.30 CHF 34.61 CHF 71.11 75

Growth DCF CHF 17.77 CHF 35.56 CHF 62.19 75

EPV CHF 32.22 CHF 37.50 CHF 42.05 74

All 26 models by family

DCF Models

FCF DCF CHF 18.30 CHF 34.61 CHF 71.11 75

Owner Earnings CHF 27.21 CHF 54.43 CHF 104.14 72

5Y Revenue Exit CHF 32.92 CHF 67.88 CHF 118.40 69

5Y EBITDA Exit CHF 54.60 CHF 115.51 CHF 197.15 72

5Y P/E Exit CHF 44.31 CHF 92.88 CHF 152.30 68

10Y Revenue Exit CHF 26.44 CHF 58.12 CHF 112.75 63

10Y EBITDA Exit CHF 42.31 CHF 93.53 CHF 181.36 64

10Y P/E Exit CHF 35.45 CHF 76.71 CHF 142.28 60

Earnings-Based

Graham-Dodd CHF 25.13 CHF 142.94 CHF 198.68 63

Lynch FV CHF 40.17 CHF 57.39 CHF 74.60 61

PEG = 1.0 CHF 40.17 CHF 57.39 CHF 74.60 57

EPV CHF 32.22 CHF 37.50 CHF 42.05 74

Dividend Discount

Gordon GGM CHF 4.98 CHF 9.93 CHF 15.03 67

DDM Multi-Stage CHF 4.98 CHF 8.58 CHF 10.48 67

Multiples

P/E Multiple CHF 60.97 CHF 81.30 CHF 101.62 63

P/S Multiple CHF 47.11 CHF 62.82 CHF 78.52 58

P/B Multiple CHF 47.11 CHF 62.82 CHF 78.52 55

EV/EBIT CHF 55.46 CHF 74.36 CHF 93.25 66

EV/EBITDA CHF 75.69 CHF 101.33 CHF 126.97 67

EV/Revenue CHF 39.23 CHF 56.57 CHF 73.91 53

Asset-Based

NCAV (Graham) CHF 8.77 CHF 11.75 CHF 17.54 54

Growth DCF

Growth DCF CHF 17.77 CHF 35.56 CHF 62.19 75

Rev-Margin DCF CHF 32.92 CHF 66.04 CHF 111.87 70

Economic Profit

Residual Income CHF 22.92 CHF 32.85 CHF 64.76 71

ROIC Compounder CHF 38.19 CHF 53.77 CHF 75.06 71

Growth Earnings

Growth-Adj P/E CHF 61.17 CHF 87.38 CHF 113.60 67

Open the full fair value analysis →

Notify me when 0A05 reaches fair value

Put 0A05 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 59/100

Of which business quality 59 · Market factors (momentum, volatility) 30

Profitability 68

Margins and returns on capital today

Quality Growth 58

Are margins and returns improving?

Cashflow 46

Earnings quality: real cash, not paper profit

Fin. Strength 76

Balance sheet, leverage, solvency risk

Investment 13

Disciplined investing over empire-building

Low Volatility 67

Calm price path (market factor)

Momentum 18

Price trend over the last 3–12 months (market factor)

52W Momentum 8

Distance to the 52-week high (market factor)

Net Issuance 81

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 86/100

Revenue is growing, but margins or cash flow do not fully confirm the trend.

Revenue growth 1 year

+16.5%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+16.3%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+17.9%

Start year 2020 (pandemic)

Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+13.6%

’16

’17

’18

’19

’20

’21

’22

’23

’24

’25

What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.

+19.5%

Earnings growth per share plus dividend.

Earnings per share, growth per year+18.5%

Dividend (yield on the price)1.0%

Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.21.0% vs −41.2%, picking up

Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.16% → 17%

2025 sits 103% above its own trend. The rate follows the median trend of the last 5 years, not that single year.

Start year 2020 (pandemic)

⚠ Revenue per share shrinking 52.6%/yr over ~7Y (margins eroding too) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.

Growth Forecast

A lot of optimism in the price

The price assumes more growth than the company has delivered so far and more than analysts expect.

What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).

+37.3%

Yearly growth needed for the next five years to justify today's price.

What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.

+10.4%

Yearly sales growth analysts expect, extended to five years.

After inflation (Switzerland: IMF forecast 0.6% a year to 2030, 0.8% from 2016 to 2025) that is about +36.5% a year for the price and +9.8% for the forecasts.

Forecast 2026 (sales)+11.1%

Forecast 2027 (sales)+12.2%

Projected 2028 (sales)+10.9%

Projected 2029 (sales)+9.6%

Projected 2030 (sales)+8.4%

0A05 screens overvalued: fair value 23% below the price. Compare with Abbott Laboratories, →

Compare Medacta Group with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 351 stocks

Beats the industry median on 7/11 measures

Overall it ranks above its industry peers.

Valuation

Quality Score 59 · Above median

Fair Value upside −31.5% · Below median

Profitability

Return on equity (TTM) 22.8% · Top 25%

Return on assets 8.4% · Top 25%

Net margin (TTM) 14.0% · Above median

Operating margin (TTM) 16.0% · Top 25%

Growth and dividend

Revenue growth 12.5% · Above median

Dividend yield (TTM) 1.0% · Below median

Balance sheet

Debt / equity 0.14× · Above median

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/E (TTM) 0.5× · Cheapest 25%

P/FCF 121.4× · Priciest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
Abbott Laboratories, ABT	$98.83	$74.79	−24%
Medtronic plc MDT	$87.09	$65.61	−25%
Stryker Corporation SYK	$278.77	$306.65	+10%
Boston Scientific Corporation BSX	$43.65	$48.02	+10%
Edwards Lifesciences Corporation EW	$85.19	$81.94	−4%
Siemens Healthineers AG SHL	€37.86	€35.19	−7%
DexCom, Inc DXCM	$86.68	$95.35	+10%
GE HealthCare Technologies Inc GEHC	$66.63	$70.37	+6%
Shenzhen Mindray Bio-Medical Electronics Co 300760	¥153.86	¥169.25	+10%
Koninklijke Philips N.V PHIA	€21.87	€15.23	−30%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Medacta Group · Fair Value
CHF 86.83 −23%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/0A05" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Medacta Group · Fair Value</span><br><b style="font-size:20px">CHF 86.83</b> <span style="color:#e0816f;font-weight:700;font-size:14px">−23%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Medacta Group Fair Value". https://www.fairvalue-calculator.com/stock/0A05

Frequently asked questions

Is Medacta Group (0A05) overvalued or undervalued?

As of Sep 24, 2026, our model estimates a fair value of CHF 86.83 versus a price of CHF 113.00, about −23% upside (overvalued).

What is the fair value of 0A05?

Our model-based fair value for Medacta Group is CHF 86.83 (as of Sep 24, 2026), built from audited fundamentals. The current price: CHF 113.00.

What is the quality score of 0A05?

Medacta Group has a Quality Score of 59/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Medacta Group (0A05)?

Our model-based price target is the fair value of CHF 86.83 (as of Sep 24, 2026) from 26 valuation models. Cautious scenario CHF 43.40, optimistic scenario CHF 147.75. It is a calculation from audited fundamentals, not an analyst target.

What is the Medacta Group stock forecast for 2026?

Our models put fair value at CHF 86.83, about −23% upside versus a price of CHF 113.00 (overvalued). Cautious scenario CHF 43.40, optimistic scenario CHF 147.75. The calculation is refreshed regularly with new filings.

What is the revenue of Medacta Group (0A05)?

Medacta Group reported trailing-twelve-month revenue of about CHF 684M (latest available figure, as of Sep 24, 2026).

Does Medacta Group pay a dividend?

Medacta Group currently shows a dividend yield of about 1.05% relative to its recent price (as of Sep 24, 2026).

What growth is priced into Medacta Group (0A05)?

For today's price to be fair in a discounted-cash-flow model, Medacta Group would have to grow free cash flow by +37.3 % per year for five years (discount rate 10.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +17.9 % per year. As of Sep 24, 2026.

What discount rate (WACC) does the fair value of 0A05 use?

Our models discount Medacta Group at 10.3 %: a base by market capitalisation (mid), damped by beta 0.99, country premium for United Kingdom. The same rate applies in all 26 models.

What is a reverse DCF?

A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Medacta Group that is +37.3 % per year a year over ten years, using the same discount rate (10.3 %) and the same formula as our fair value.

How much growth has Medacta Group (0A05) delivered so far?

Over the past 5 years revenue at Medacta Group grew +17.9 % a year. The price currently implies +37.3 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.

How fast is the sector of Medacta Group (0A05) growing?

The median revenue growth in the sector is +7.2 % a year. That is the yardstick for the growth priced into Medacta Group (+37.3 % per year a year): it shows whether the expectation is within the usual range or beyond it.

What is the free cash flow yield of Medacta Group (0A05)?

The free-cash-flow yield on the price is 1.32 %: that much free cash flow Medacta Group produces per unit of market value. When it exceeds the discount rate of our models (10.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.

What is the intrinsic value of Medacta Group (0A05)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Medacta Group it is CHF 86.83 per share (as of Sep 24, 2026), against a price of CHF 113.00. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).

Is Medacta Group stock overvalued or undervalued in 2026?

As of Sep 24, 2026, 0A05 trades above its calculated fair value: price CHF 113.00, fair value CHF 86.83, a gap of about −23% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of 0A05?

No. The price is what the market pays today (CHF 113.00); the fair value is what the company's own numbers justify (CHF 86.83). For Medacta Group the two are CHF 26.17 per share apart. That gap is exactly why we show both numbers side by side.

How much is Medacta Group worth?

The market values Medacta Group at about CHF 2.9B (market capitalisation, as of Sep 24, 2026). Per share that is CHF 113.00; our models calculate a fair value of CHF 86.83 per share.

What do the bullish and bearish scenarios say about 0A05?

Our models span a range for Medacta Group: cautious scenario CHF 43.40, base CHF 86.83, optimistic CHF 147.75 per share (as of Sep 24, 2026, price CHF 113.00). The range comes from different growth and margin assumptions, not from analyst opinions.

What is the P/E ratio of 0A05?

Medacta Group trades at a price-to-earnings ratio of 0.5 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of CHF 86.83 is built from several models across several years.

How solid is the balance sheet of Medacta Group (0A05)?

Balance-sheet figures for Medacta Group (as of Sep 24, 2026): return on equity 22.8%, debt of 0.14 per unit of equity. They feed the Quality Score of 59/100, which measures business quality independently of the share price.

How far is 0A05 from its 52-week high?

Medacta Group trades at CHF 113.00, about 35% below its 52-week high of CHF 174.45 and 4% above the low of CHF 109.00 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of CHF 86.83 is for.

Which stocks are comparable to Medacta Group?

From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Medacta Group stock attractive at the current price?

The data as of Sep 24, 2026: price CHF 113.00, calculated fair value CHF 86.83 (−23%), Quality Score 59/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of 0A05 calculated?

We run Medacta Group through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of CHF 86.83, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 14.5 % above its aggregate fair value. Medacta Group itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Medacta Group (0A05)?

The closing price on Oct 2, 2026 was CHF 113.00. Our model-based fair value is CHF 86.83, about −23% upside (overvalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Medacta Group right now?

The model range is unusually wide (CHF 43.40 to CHF 147.75). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid but not exceptional quality (59/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of Medacta Group

How large is the market capitalisation of Medacta Group (0A05)?

The market capitalisation of Medacta Group is CHF 2.9B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of Medacta Group (0A05)?

The price-to-sales ratio of Medacta Group is 0.07 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of Medacta Group (0A05)?

Earnings per share at Medacta Group are CHF 2.62 (price ÷ EPS = P/E 0.5). Earnings per share over the last twelve months: total profit spread across every single share.

What is the dividend yield of Medacta Group (0A05)?

The dividend yield of Medacta Group is 1.0% (payout 45.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.

What is the net margin of Medacta Group (0A05)?

The net margin of Medacta Group is 14.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of Medacta Group (0A05)?

The return on equity (ROE) of Medacta Group is 22.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Medacta Group (0A05)?

On an EBIT basis the return on assets of Medacta Group is 11.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Medacta Group (0A05)?

The operating margin of Medacta Group is 16.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Medacta Group (0A05)?

Revenue at Medacta Group is growing +12.5% versus a year earlier (3y avg +16.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at Medacta Group (0A05)?

Earnings per share at Medacta Group are growing +1.2% versus a year earlier. How much earnings per share grew versus a year earlier.

How much net debt does Medacta Group (0A05) carry?

The net debt of Medacta Group is CHF 229M (fiscal year 2025, ≈ 7.7 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.

Free · no account needed

Watch Medacta Group in the live analysis

One click puts Medacta Group on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.